Skip to main content

Modern PCI

Outcomes for a lifetime

A holistic approach that produces the best possible outcomes in trial after trial

Having taken the preparation steps proven to reduce risk and increase long-term success, you now have a suite of market-leading therapies at your fingertips. You’ll have everything you need to give the best quality of life to your patients.

AGENTTM Drug-Coated Balloon (DCB)

  • Introduces a new treatment option for patients with in-stent restenosis (ISR)
  • Has demonstrated consistently low rates of target lesion revascularization, stent thrombosis, and late lumen loss1
  • Purposefully designed to provide reliable and efficient drug transfer exactly where its needed
  • Designed to provide effortless deliverability in complex anatomy
SYNERGY™ XD: Bioabsorbable Polymer Drug-Eluting Stent

SYNERGY™ XD: Bioabsorbable Polymer Drug-Eluting Stent

  • Innovative delivery system for increased pushability and trackability
  • Customized stent architecture for strength and flexibility where it’s needed
  • Intentionally designed with thin struts and a fast-absorbing polymer to enable short DAPT
  • Indicated for use in high bleeding risk patients
SYNERGY™ XD: Bioabsorbable Polymer Drug-Eluting Stent

SYNERGY MEGATRON™: Drug-eluting stent with mega strength

  • Single, versatile model purpose-built for large proximal vessels
  • Unmatched overexpansion with uniform scaffolding to accommodate wide diameter mismatch
  • Best-in-class radial and axial strength to promote stent integrity
  • Bioabsorbable polymer is gone shortly after the drug is eluted
  • Maximum visibility to aid in accurate stent placement
SYNERGY MEGATRON™: Drug-eluting stent with mega strength

Our Modern PCI treatment products

Clinical data: Studies show Modern PCI stents improve treatment success

AGENT IDE Clinical Trial 

Results from the first coronary DCB study in the U.S. successfully achieved the primary endpoint at the 1-year mark, revealing favorable rates of adverse events. The AGENT IDE Clinical Trial further substantiated the superiority of AGENT DCB over traditional balloon angioplasty in mitigating target lesion failure for the treatment of coronary ISR.

Read about the AGENT IDE Trial

SYNERGY BP Stents reduce stent thrombosis

In the Kang Meta-Analysis, SYNERGY was ranked #1 for lowest relative risk of definite/probably stent thrombosis at one year, when compared to other stents in the industry. In the SCAAR Registry, the SYNERGY BP Stent had the lowest rate of stent thrombosis at one year compared to other new generation DES, despite being used in statistically more complex patients.

Read about the Kang Meta-Analysis and SCAAR Registry.

Proven excellent outcomes with short DAPT

SYNERGY BP stents are intentionally designed with thin struts and a fast absorbing, abluminal polymer to enable short DAPT. SYNERGY has been studied with various DAPT durations in a variety of patient populations. The EVOLVE Short DAPT Trial showed that the SYNERGY BP Stent demonstrated low stent thrombosis in the 12 months following 3-month DAPT.

Read about the EVOLVE Short DAPT Trial.

Training and education

Our EDUCARE platform gives you instant, online access to a wealth of clinical education, all in one convenient place.

woman on a tablet

Join EDUCARE for best-in-class learning

Learn from top operators about the use of the AGENT DCB in Modern PCI, optimizing treatment for patients, and clinical data and outcomes. Register or log in to EDUCARE, our free online education platform, to watch now.

Educational Events

Boston Scientific offers live events and training on Modern PCI topics, including:

  • Calcium management
  • IVUS
  • Coronary physiology
  • CTOs
  • ROTAPRO™ certification

View all training for Coronary Interventions

Connect with us

Talk to a rep

Fill out a short form and one of our sales representatives will be in touch with you.

Receive updates

Stay informed on the latest advancements surrounding our products and solutions.

1. Scheller B, Rissanen TT, Farah A, et al. Drug-coated balloon for small coronary artery disease in patients with and without high-bleeding risk in the BASKET-SMALL 2 trial. Circ Cardiovasc Interv. 2022;15:e011569.